The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...
A newly identified metabolite in human feces improves immunotherapy and could radically change the treatment of lung cancer.
Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.
Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...
Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.
Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.
Summit Therapeutics Inc.’s presentation for bispecific antibody ivonescimab in non-small-cell lung cancer could draw some extra attention at next month’s World Conference on Lung Cancer meeting thanks ...
Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...
The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a previously unrecognized driver of immunotherapy resistance and metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results